Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Launched by BOEHRINGER INGELHEIM · Jan 28, 2013
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Signed and dated ICF (Informed Consent Form)
- • 2. Male or female on diet and exercise regime and on stable background metformin \> or equal to 1500 mg or maximun dose according to local label
- • 3. HBA1c (Glicoslated Hemoglobin) \> or equal to 8% and \< or equal to 10.5 % at Visit 1
- • 4. HbA1c \> or equal to 7 and \< or equal to 10.5 at Visit 4
- • 5. Age \> or equal to 18 years
- • 6. BMI (Body Mass Index) \< or equal to 45
- Exclusion criteria:
- • 1. Uncontrolled hyperglycemia during open label period and placebo add on "run-in" period
- • 2. Use of any other antidiabetic
- • 3. Renal function below 60 ml/min/1.73 m2
- • 4. Antiobesity drugs or aggresive diets
- • 5. Gastorintestinal surgeries
- • 6. Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type 2
- • 7. Acute coronary syndrome and stroke within 3 months of informed consent
- • 8. Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chino, California, United States
Huntington Beach, California, United States
San Diego, California, United States
San Diego, California, United States
Sylmar, California, United States
Miami, Florida, United States
Orlando, Florida, United States
Oviedo, Florida, United States
Tamarac, Florida, United States
Conyers, Georgia, United States
Snellville, Georgia, United States
Avon, Indiana, United States
Muncie, Indiana, United States
Elkton, Maryland, United States
Stevensville, Michigan, United States
Salisbury, North Carolina, United States
Bismarck, North Dakota, United States
Oklahoma City, Oklahoma, United States
Pittsburgh, Pennsylvania, United States
Union, South Carolina, United States
North Richland Hills, Texas, United States
Draper, Utah, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
Caba, , Argentina
Caba, , Argentina
Capital Federal, , Argentina
Capital Federal, , Argentina
Capital Federal, , Argentina
Cordoba, , Argentina
Cordoba, , Argentina
Córdoba, , Argentina
Godoy Cruz, Mendoza, , Argentina
Mar Del Plata, , Argentina
Salta, , Argentina
San Isidro, , Argentina
Zarate, , Argentina
Cardiff, New South Wales, Australia
East Ringwood, Victoria, Australia
Heidelberg Heights, Victoria, Australia
Mirrabooka, Western Australia, Australia
Edmonton, Alberta, Canada
Red Deer, Alberta, Canada
Chilliwack, British Columbia, Canada
Coquitlam, British Columbia, Canada
Vancouver, British Columbia, Canada
Winnipeg, Manitoba, Canada
Winnipeg, Manitoba, Canada
Moncton, New Brunswick, Canada
Burlington, Ontario, Canada
Strathroy, Ontario, Canada
Sudbury, Ontario, Canada
Drummondville, Quebec, Canada
Montreal, Quebec, Canada
ávila, , El Salvador
Asslar, , Germany
Berlin, , Germany
Elsterwerda, , Germany
Hamburg, , Germany
Hatten, , Germany
Kiel Kronshagen, , Germany
Köln, , Germany
Lübeck, , Germany
Münster, , Germany
Pirna, , Germany
St. Ingbert/Oberwürzbach, , Germany
Unterschneidheim, , Germany
Wangen, , Germany
Ancona, , Italy
Catania, , Italy
Catania, , Italy
Catania, , Italy
Latina, , Italy
Milano, , Italy
Milano, , Italy
Olbia (Ot), , Italy
Orbassano (To), , Italy
Palermo, , Italy
Pistoia, , Italy
Roma, , Italy
Sesto San Giovanni (Mi), , Italy
Siena, , Italy
Terni, , Italy
Cantanhede, , Portugal
Porto, , Portugal
Sandim, , Portugal
Tornada, , Portugal
Valadares, , Portugal
Vila Nova De Gaia, , Portugal
Chelyabinsk, , Russian Federation
Saint Petersburg, , Russian Federation
Saratov, , Russian Federation
Saratov, , Russian Federation
St. Petersburg, , Russian Federation
Yaroslavl, , Russian Federation
Barcelona, , Spain
Canet De Mar, , Spain
Centelles, , Spain
L'hospitalet De Llobregat (Barcelona), , Spain
La Roca Del Vallès, , Spain
Madrid, , Spain
Malaga, , Spain
Mataró, , Spain
Málaga, , Spain
Pineda De Mar, , Spain
Sabadell, , Spain
Tarragona, , Spain
Chernivtsi, , Ukraine
Dnipropetrovs'k, , Ukraine
Kiev, , Ukraine
Kiev, , Ukraine
Lviv, , Ukraine
Vinnitsa, , Ukraine
Zhytomyr, , Ukraine
Patients applied
Trial Officials
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials